Covidien’s Mark Turco Discusses Physicians’ Plight In New Health Care System
This article was originally published in The Gray Sheet
The CMO for Covidien’s vascular business says in a Q&A with “The Gray Sheet” that physicians are on board with the ongoing changes to the health care system, but it is vital that companies and doctors work together to encourage sensible new-technology adoption.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.